Hilgendorf I, Scholl S, Sayer H, Mügge LO, Hochhaus A, von Lilienfeld-Toal M Melphalan 200 mg/m 2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma [...] Hochhaus A, von Lilienfeld-Toal M, Mügge LO. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)
collagenase expression in chronic idiopathic myelofibrosis (cIMF) is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol 2006; 169(2): 471-481 Bornemann J, Hagner D, Brandenburg R [...] Ballmaier M, Bormann M, Göhring G, Buhr T, Bock O, Kreipe H: B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol 2006; 77(6): 539-41 Ikuerowo SO, Kuczyk [...] 119(4): 867-74 Jörns A, Rath KJ, Bock O, Lenzen S. Beta cell death in hyperglycaemic Psammomys obesus is not cytokine-mediated. Diabetologia 2006; 49(11): 2704-12 Kersting C, Packeisen J, Leidinger B, Brandt
betreten die MHH durch den Haupteingang (Gebäude K6) und gehen durch die Ladenstraße bis zum Fahrstuhlknoten_A . Dort fahren Sie mit dem Personenaufzug bis in die Etage S0 und steigen nach links aus. Sie
FTSS) IIHS Highway Safety-Related Sites IIHS Safety Facts IIHS Vehicle Ratings Reports and Research Notes (NHTSA - NCSA) Institut für Land- und Seenverkehr - Fachgebiet Kraftfahrzeuge (ILS)
in fragments of about 1000 nucleotides, the so-called Okazaki fragments. Since DNA polymerases are not able to start DNA synthesis de novo, each Okazaki fragment has to begin with an RNA primer provided
for the October 2026 intake can be submitted between 1st December 2025 and 1st March 2026. Please note that we only accept applications made through our online system which can be found here: https://hbrs
analysis of large datasets. If you are interested to join us feel free to get in touch (especially but not exclusively MD or PhD students) at Engel.Bastian@mh-hannover.de . Weitere Informationen Publikationen
for the October 2026 intake can be submitted between 1st December 2025 and 1st March 2026. Please note that we only accept applications made through our online system which can be found here: https://hbrs
betreten die MHH durch den Haupteingang (Gebäude K6) und gehen durch die Ladenstraße bis zum Fahrstuhlknoten_C . Dort fahren Sie mit dem Personenaufzug bis in die Etage 3 . Sie gelangen so unmittelbar vor
Materialien 10-15 ml Knochenmarkaspirat (Heparin / EDTA) 10-15 ml peripheres Blut (Heparin / EDTA) Lymphknotengewebe (in 0,9% NaCl-Lösung) Anderes Tumorgewebe (in 0,9% NaCL-Lösung) Liquorpunktat (nativ) Pleurapunktat